- •Niacin plus omega-3 therapy was tested in overweight dyslipidemic patients.
- •This combination is more potent in normalizing apolipoprotein parameters.
- •These changes are consistent with effects of this combination on plasma lipids.
- •Combo therapy normalized apoC3 glycosylation.
Prescription omega-3 acid ethyl esters (P-OM3) and extended release niacin (ERN) both have beneficial effects on plasma lipids and lipoproteins. The purpose of this study was to describe the effects of mono- and combination (Combo) therapy of these agents in patients with the metabolic syndrome.
Very low density (VLDL), intermediate/low density (IDL/LDL, hereafter LDL), and high density lipoproteins (HDL) were isolated from 56 overweight patients with elevated triglyceride/HDL-C ratios at baseline and after 16 weeks of treatment with placebo, ERN (2g/day), P-OM3 (4g/day), or Combo and then analyzed by quantitative electrophoresis for apolipoproteins (apo) A1, A2, B, C2, C3 and E. Total plasma concentrations and the ratios of each apo with apoB (in VLDL and LDL) and with apoA1 (in HDL) were calculated. An apoC3 glycosylation index (a ratio between di- and mono-sialylated isoforms) was also determined in plasma and in each lipoprotein fraction.
ERN reduced plasma apoB (−11%, p < 0.05). Combo increased LDL apoE/apoB ratio (64%, p < 0.01) and LDL apoA1/apoB (91%, p < 0.05). ERN increased the apoC3 glycosylation index only in HDL (37%, p < 0.05), whereas P-OM3 and Combo increased the index in whole plasma (48% and 49%, respectively, p < 0.05 for both) and in every lipoprotein class (VLDL: 26%, p < 0.01 and 26%, p < 0.05; LDL: 55%, p < 0.01 and 61%, p < 0.01; HDL: 43%, p < 0.001 and 44%, p < 0.001, respectively). All findings were significant after adjustment for age, sex, body mass index (BMI), smoking, medications, and baseline apo value.
ERN produced a beneficial reduction in plasma apoB. The enrichment of LDL with apoE and apoA1 was unique to the Combo group and might be beneficial owing to the atheroprotective properties of apoE and HDL2 (a likely source of apoA1 in LDL fraction). The effect of therapies on the apoC3 glycosylation index is a novel finding, the implications of which will require further study.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Atherosclerosis
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999–2010.J. Am. Coll. Cardiol. 2013; 62: 697-703
- Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood Institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity.Circulation. 2009; 120: 1640-1645
- The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis.J. Am. Coll. Cardiol. 2010; 56: 1113-1132
- Metabolic syndrome and risk of cardiovascular disease: a meta-analysis.Am. J. Med. 2006; 119: 812-819
- Evaluation and treatment of hypertriglyceridemia: an endocrine society clinical practice guideline.J. Clin. Endocrinol. Metab. 2012; 97: 2969-2989
- 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint National Committee (JNC 8).JAMA. 2014; 311: 507-520
- Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the study of Diabetes.Diabetes Care. 2006; 29: 1963-1972
- Influence of nicotinic acid on serum cholesterol in man.Arch. Biochem. Biophys. 1955; 54: 558-559
- Changes in concentration of blood lipids following prolonged administration of large doses of nicotinic acid to persons with hypercholesterolemia: preliminary observations.Proc. Staff Meet. Mayo Clin. 1956; 31: 377-390
- Fifteen year mortality in coronary drug project patients: long-term benefit with niacin.J. Am. Coll. Cardiol. 1986; 8: 1245-1255
- Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia.Am. J. Cardiol. 1998; 82: 737-743
- Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.Clin. Ther. 2007; 29: 1354-1367
- Safety and efficacy of Omacor in severe hypertriglyceridemia.J. Cardiovasc. Risk. 1997; 4: 385-391
- Niacin, an old drug with a new twist.J. Lipid Res. 2013; 54: 2586-2594
- Nicotinic acid as a lipid-modifying drug–a review.Atheroscler. Suppl. 2013; 14: 7-13
- The role of niacin in lipid-lowering treatment: are we aiming too high?.Curr. Pharm. Des. 2013; 19: 3094-3106
- Fish oil – how does it reduce plasma triglycerides?.Biochim. Biophys. Acta. 2012; 1821: 843-851
- Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A(2) mass in statin-treated subjects with hypertriglyceridemia.J. Clin. Lipidol. 2009; 3: 332-340
- Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.N. Engl. J. Med. 2011; 365: 2255-2267
- OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.Circulation. 2010; 122: 2152-2159
- Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis.JAMA. 2012; 308: 1024-1033
- Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione.Circulation. 2002; 105: 1897-1903
- Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial.Expert Rev. Cardiovasc. Ther. 2009; 7: 735-748
- Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.Lancet. 2007; 369: 1090-1098
- Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial.J. Lipid Res. 2012; 53: 2429-2435
- Reduced apolipoprotein glycosylation in patients with the metabolic syndrome.PLoS One. 2014; 9: e104833
- Sequential flotation ultracentrifugation.Methods Enzymol. 1986; 128: 155-170
- A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk.Circ. Cardiovasc. Qual. Outcomes. 2011; 4: 337-345
- Meta-analysis of comparison of effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials.Am. J. Cardiol. 2012; 110: 1468-1476
- Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis intervention in metabolic syndrome with low HDL/High triglyceride and impact on global health Outcomes).J. Am. Coll. Cardiol. 2013; 62: 1575-1579
- Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study.J. Clin. Lipidol. 2013; 7: 615-625
- Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.J. Clin. Lipidol. 2011; 5: 483-492
- Omega-3 ethyl ester concentrate decreases total apolipoprotein CIII and increases Antithrombin III in postmyocardial infarction patients.Clin. Drug Investig. 1998; 15: 473-482
- Apolipoprotein E and atherosclerosis: insight from animal and human studies.Clin. Chim. Acta. 1999; 286: 115-143
- Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study).Atherosclerosis. 2007; 192: 432-437
- Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort.Atherosclerosis. 2011; 214: 196-202
- O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease.J. Proteome Res. 2009; 8: 603-612
- Effects of severe caloric restriction on the degree of sialylation of apoprotein C-III in obese women.Ann. Nutr. Metab. 1985; 29: 33-39
- Presence of Apo B48, and relative Apo CII deficiency and Apo CIII enrichment in uremic very-low density lipoproteins.Ann. Biol. Clin. (Paris). 1989; 47: 497-501
- Isolation of atherogenic modified (desialylated) low density lipoprotein from blood of atherosclerotic patients: separation from native lipoprotein by affinity chromatography.Biochem. Biophys. Res. Commun. 1990; 167: 1122-1127
- Modification of low density lipoprotein by desialylation causes lipid accumulation in cultured cells: discovery of desialylated lipoprotein with altered cellular metabolism in the blood of atherosclerotic patients.Biochem. Biophys. Res. Commun. 1989; 162: 206-211
- Carbohydrate composition of protein and lipid components in sialic acid-rich and -poor low density lipoproteins from subjects with and without coronary artery disease.J. Lipid Res. 1993; 34: 365-375
- Sialic acid-containing components of lipoproteins influence lipoprotein-proteoglycan interactions.Atherosclerosis. 1999; 145: 253-260
- Effects of extended-release niacin with laropiprant in high-risk patients.N. Engl. J. Med. 2014; 371: 203-212
- The therapeutic role of niacin in dyslipidemia management.J. Cardiovasc. Pharmacol. Ther. 2014; 19: 141-158
- Niacin: a long history, but a questionable future.Curr. Opin. Lipidol. 2013; 24: 475-479
- Are n-3 fatty acids still cardioprotective?.Curr. Opin. Clin. Nutr. Metab. Care. 2013; 16: 141-149
- Pitfalls in the use of randomised controlled trials for fish oil studies with cardiac patients.Br. J. Nutr. 2014; 112: 812-820
- Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.JAMA. 2001; 285: 1585-1591
Published online: April 22, 2015
Accepted: April 21, 2015
Received in revised form: March 27, 2015
Received: October 23, 2014
© 2015 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.